Details

Autor(en) / Beteiligte

• Ledder, Oren
• Assa, Amit
• Levine, Arie
• Escher, Johanna C
• de Ridder, Lissy
• Ruemmele, Frank
• Shah, Neil
• Shaoul, Ron
• Wolters, Victorien M
• Rodrigues, Astor
• Uhlig, Holm H
• Posovsky, Carsten
• Kolho, Kaija-Leena
• Jakobsen, Christian
• Cohen, Shlomi
• Shouval, Dror S
• de Meij, Tim
• Martin-de-Carpi, Javier
• Richmond, Lisa
• Bronsky, Jiri
• Friedman, Mira
• Turner, Dan

Titel

Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN

Ist Teil von

• Journal of Crohn's and colitis, 2017-10, Vol.11 (10), p.1230-1237

Ort / Verlag

UK: Oxford University Press

Erscheinungsjahr

2017

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort. Method Retrospective review of children [aged 2–18 years] treated with vedolizumab from 19 centres affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was Week 14 corticosteroid-free remission [CFR]. Results In all, 64 children were included (32 [50%] male, mean age 14.5 ± 2.8 years, with a median follow-up 24 weeks [interquartile range 14–38; range 6–116]); 41 [64%] cases of ulcerative colitis/inflammatory bowel disease unclassified [UC/IBD-U] and 23 [36%] Crohn’s disease [CD]. All were previously treated with anti-tumour necrosis factor [TNF] [28% primary failure, 53% secondary failure]. Week 14 CFR was 37% in UC, and 14% in CD [P = 0.06]. CFR by last follow-up was 39% in UC and 24% in CD [p = 0.24]. Ten [17%] children required surgery, six of whom had colectomy for UC. Concomitant immunomodulatory drugs did not affect remission rate [42% vs 35%; p = 0.35 at Week 22]. There were three minor drug-related adverse events. Only 3 of 16 children who underwent endoscopic evaluation had mucosal healing after treatment (19%). Conclusions Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC.